FIELD: biotechnology.
SUBSTANCE: invention relates to the field, specifically to modified T-cells, and can be used in medicine for stimulation of immune response to HPV antigen and treatment of HPV-associated cancer. Disclosed is a modified T-cell containing a human papilloma virus (HPV) antigen, derived from HPV-16 or HPV-18, and an adjuvant, which is selected from CpG-oligodeoxynucleotide (ODN), IFN-α, STING agonists, RIG-I agonists, imiquimod (R837), resiquimod (R848) or lipopolysaccharide (LPS).
EFFECT: invention provides obtaining a modified T-cell capable of inducing an endogenous specific immune response against the HPV antigen when administered to a subject in need thereof.
70 cl, 22 dwg, 1 tbl, 22 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATMENT OF DISEASES ASSOCIATED WITH HPV | 2019 |
|
RU2799784C2 |
| DELIVERY OF BIOMOLECULES INTO CELLS OF IMMUNE SYSTEM | 2015 |
|
RU2739794C2 |
| RECOMBINANT PROTEIN CARRYING HUMAN PAPILLOMA VIRUS EPITOPES, PROTEIN EMBEDDED ADENYLATECYCLASE OR ITS FRAGMENT, ITS THERAPEUTIC APPLICATION | 2005 |
|
RU2441022C2 |
| IMMUNOGENIC COMPOSITION BASED ON RECOMBINANT PROTEINS E6-CBD AND E7-CBD FOR THE TREATMENT OF MALIGNANT NEOPLASMS ASSOCIATED WITH HUMAN PAPILLOMAVIRUS TYPE 16 | 2023 |
|
RU2805482C1 |
| IMMUNOSTIMULATORY OLIGONUCLEOTIDES | 2012 |
|
RU2610690C2 |
| VACCINE CONTAINING RIBOSOMAL PROTEIN EXTRACT (RPE) AND Th1-ACTIVATING ADJUVANT | 2009 |
|
RU2521499C2 |
| METHODS FOR INCREASING EFFECTIVENESS OF ANTITUMOUR IMMUNE RESPONSE | 2015 |
|
RU2689162C2 |
| INTRACELLULAR DELIVERY OF BIOMOLECULES FOR TOLERANCE INDUCTION | 2017 |
|
RU2747878C2 |
| IMMUNOSTIMULATING PHOSPHOROTHIOATE CpG-OLIGONUCLEOTIDES, CONTAINING PHOSPHODIESTER LINKS, METHOD OF IMMUNOMODULATION, METHOD OF IMMUNE RESPONSE STIMULATION | 2003 |
|
RU2338750C2 |
| IMMUNOSTIMULATING COMPOSITIONS | 2016 |
|
RU2732118C2 |
